The corona virus continues to make headlines worldwide. Many experts are now using the malaria drug chloroquine as a possible remedy. Bayer now wants to produce the active ingredient in Europe.
- The corona virus * continues to spread.
- Meanwhile, you’re looking for one drug.
- Numerous experts are now placing hopes on this Malaria drug chloroquine.
–
Update from April 2, 2020, 10:39 a.m .: Of the Pharmaceutical and chemical company Bayer wants to fight the lung disease Covid-19 now too in Europe production opportunities for the Create active ingredient chloroquine. Bayer CEO Werner Baumann announced on Thursday in an interview with the Handelsblatt that production facilities in Europe should also be adapted for the manufacture of the drug resochin with the active ingredient chloroquine.
Coronavirus: Bayer plans to make chloroquine available free of charge in the Covid 19 crisis
So far, the means that Bayer wants to donate to governments free of charge in the corona crisis has only been manufactured in one location in Pakistan. The drug developed in the 1930s for Malaria prophylaxis has been for a few weeks possible active ingredient against Covid-19 in conversation. The reason for this is that tests on cell cultures had shown an inhibition of the multiplication of the novel corona virus. “There are indications that Resochin reduces the viral load in the laboratory and in initial clinical tests,” Baumann told the Handelsblatt. But be it further clinical studies necessaryto clarify the relationship between risk and benefit. These studies would now be launched by the World Health Organization (WHO), among others.
After US president Donald Trump had promoted the use of chloroquine in the treatment of Covid 19 sufferers, the malaria drug had also come into focus outside of specialist circles. Experts are over possible side effects but be careful and warn against self-medication. In France, for example, the treatment of people suffering from Covid 19 is only permitted if the course is severe and after consultation with doctors.
Coronavirus: Swiss pharmaceutical company has hopes in malaria drug
Update from March 29, 2020, 10:55 p.m .: Again there is the Look for a cure for the corona virus News that at least gives rise to hope: the Swiss pharmaceutical company Novartis Has great expectations for the malaria drug hydroxychloroquine. “Preclinical studies with animals and initial data from clinical studies show that it kills the coronavirus,” Novartis boss Vasant Narasimhan told the SonntagsZeitung. Patients are currently being sought for clinical studies in Europe and the USA. In cooperation with the supervisory authorities in the USA and Switzerland, a Approval checked by express procedure.
At the same time other drugs already developed were then examinedwhether they are for the Use against Covid-19 would come into question. The cancer drug Jakavi is “very promising”, said the Novartis boss. In addition, the multiple sclerosis drug Gilenya and Ilaris, a drug for febrile syndromes, would be examined for possible use.
Update from March 18, 2020, 6:29 p.m .: The Tübingen Institute for Tropical Medicine already wants to test one possible next week Anti-coronavirus drug start (see below).
And also the WHO has a large-scale study initiated. Five drugs are to be tested for their effectiveness against the coronavirus. Hospitals in nine countries are already participating in the study. Germany has not been mentioned so far. The first too Tests for a vaccine have already started, reports the dpa.
Also read: Breakthrough for German researchers – crucial enzyme for virus replication has now been decoded.
Coronavirus: Tübingen doctors want to test drug against CoVid-19
Update from March 18, 2020, 12.54 p.m .: Apparently there is further progress in the search for one Anti-coronavirus drug: The Tübingen Institute for Tropical Medicine wants the drug Chloroquine in the fight against corona diseases. A study on humans is scheduled to start as early as next week, institute director Peter Kremser said on Wednesday. Previously, the SWR reported.
Coronavirus: Chloroquine is currently on the market as an active ingredient against malaria
According to Kremsner, chloroquine has long been considered Active ingredient against malaria on the market. But it helps against many viruses – also against Sars-CoV-2. At least this was shown by tests in a test tube. In Italy and China According to Kremsner,Many CoVid-19 patients treated with chloroquine been. However, it is unclear whether the treatment was successful because the patients had received chloroquine in very high doses and together with many other medications. “It may also not work or even harm you“Warned Kremsner.
With chloroquine, the Tübingen tropical doctors now want one Treat test group suffering from CoVid-19 moderately and a placebo control group. The application for the study should be submitted to the Tübingen Ethics Committee today.
Basically, drugs are only ever approved for certain diseases. The Bonn Federal Institute for Drugs and Medical Devices (BfArm) is responsible for this. Deviating from this, doctors can only give medication in trials to individual patients in exceptional cases.
Update from March 13, 2020, 9.55 a.m .: The search for one Active ingredient against the corona virus SARS-CoV-2 continues to run at full speed. While the Number of infected meanwhile on 2750 has risen, the NDR reports on a new one Active ingredient from Lübeckthat is supposed to help against the virus.
Coronavirus: Researchers from Lübeck develop active ingredient
According to a team of researchers Professor Rolf Hilgenfeld the University of Lübeck developed an active ingredient. He and his team currently have an incredible workload. “We spend up to 18 hours here in the laboratory,” the head of the Institute of Biochemistry told the Lübecker Nachrichten.
As reported by NDR.de, the active ingredient is said to alreadytested in human lung cells been with the SARS-CoV-2 are infected. According to Professor Hilgenfeld, the active ingredient is active. According to his approach, he is supposed to render the viruses in the lungs harmless. The active ingredient is said to paralyze the enzyme that the virus needs to enter the lungs.
Coronavirus: a long way from drug to drug
The team around Hilgenfeld will soon be presenting the results in the renowned scientific journal “Science”. So far, there is no mention of a drug that can be used. It was still one long way Hilgenfeld says that it can be used to make a drug out of the active substance in the laboratory.
Animal experiments on mice would have to be carried out, and the active ingredient would also have to be tested on both healthy and sick volunteers. Side effects tests should also be performed. “It may take some time before the right medication is in the pharmacy,” said the researcher, but is still optimistic that it could go faster in this case. The background to this is 140 million that the household has made available to advance research.
However, time could make a huge spanner in the works. One of the main problems with the development of active substances is that there can be no more sick people when the drug is ready for a test phase.
In China, where the coronavirus first broke out, the peak of the spread appears to have passed. According to official statistics, China has reported significantly fewer new infections and deaths in recent days.
Coronavirus: Potential drug found – it could help in the short term: “Have found that …”
Munich – The Corona virus spreads further. The situation in Italy after the outbreak of the corona virus is serious. There are now almost 6,000 infected and over 230 dead (as of March 8, 2020). In Italy, travel is now banned for almost 16 million people.
In Germany, too, the situation is getting worse because of the
Coronavirus Sars-CoV-2 *. German scientists are now on the track of a drug against the virus.
Coronavirus: TMPRSS2 Enzyme The Key To A Drug?
As the German Primate Center (DZP) Through his website, tests were carried out in collaboration with colleagues from the Charité – Universitätsmedizin Berlin to find out how the SARS-CoV-2 * coronavirus penetrates cells. Corona viruses therefore need one to penetrate the lung cells Protease or a enzyme called TMPRSS2.
“Our results show that SARS-CoV-2 needs the protease TMPRSS2 present in the human body to penetrate into the host cell.” Stefan Pöhlmann, Head of the Department of Infection Biology at the DZP. This provided a starting point for fighting the virus, Pöhlmann continued.
“An existing drug that inhibits this protease could therefore be a promising treatment option,” said the DZP.
Coronavirus drug: “Tests suggest that …”
On the Enzyme TMPRSS2 be one of those approved in Japan Drug Camostat Mesilate encountered that originally used for inflammation of the pancreas. “We tested SARS-CoV-2 from a patient and found that Camostat Mesilate blocks the entry of the virus into lung cells,” says infection biologist Dr. Markus Hoffmann quoted on the DZP website.
Video: Coronavirus – can boss ask for home office or forced vacation?
Hoffmann also confirmed to the picture (article behind payment barrier) that the results would suggest that Camostat Mesilate could also protect against the disease COVID-19. “This should be investigated in the context of clinical studies.” However, how long this will take remains unclear. So far, there is only talk of a potential drug.
So far, it has also looked rather bad for a vaccine for the corona virus. As Lothar Wieler, head of the Robert Koch Institute, said that a vaccine should not be used before 2021.
Also worth reading: How dangerous previous illnesses are in connection with the corona virus, explains a Munich doctor at tz.de *.
Corona virus: The isolation of cities like Milan and Venice shows how controversial the situation is now. Commentary from Merkur editor-in-chief Georg Anastasiadis. The corona virus has arrived in Baden-Württemberg. The RKI added the Alsace region adjacent to Baden-Württemberg as a risk area.
The corona virus keeps the whole world in suspense. Italy is in a state of emergency. But in the city of Siena, people defy the virus in a beautiful way.
mbr
* Merkur.de and tz.de are part of the nationwide Ippen-Digital editors network.
List of rubric lists: © AFP / GERARD JULIEN
–
